BR112021018611A2 - Anticorpos tendo especificidade para btn2 e usos dos mesmos - Google Patents

Anticorpos tendo especificidade para btn2 e usos dos mesmos

Info

Publication number
BR112021018611A2
BR112021018611A2 BR112021018611A BR112021018611A BR112021018611A2 BR 112021018611 A2 BR112021018611 A2 BR 112021018611A2 BR 112021018611 A BR112021018611 A BR 112021018611A BR 112021018611 A BR112021018611 A BR 112021018611A BR 112021018611 A2 BR112021018611 A2 BR 112021018611A2
Authority
BR
Brazil
Prior art keywords
specificity
antibodies
btn2
btn2a
cancer
Prior art date
Application number
BR112021018611A
Other languages
English (en)
Inventor
Foucher Etienne
Cano Carla
Suong Le Kieu
Pasero Christine
Olive Daniel
Original Assignee
Imcheck Therapeutics Sas
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Inst Jean Paoli & Irene Calmettes
Univ Aix Marseille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcheck Therapeutics Sas, Inst Nat Sante Rech Med, Centre Nat Rech Scient, Inst Jean Paoli & Irene Calmettes, Univ Aix Marseille filed Critical Imcheck Therapeutics Sas
Publication of BR112021018611A2 publication Critical patent/BR112021018611A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ANTICORPOS TENDO ESPECIFICIDADE PARA BTN2 E USOS DOS MESMOS. A presente invenção se refere a anticorpos tendo especificidade para BTN2A e usos dos mesmos, em particular para o tratamento de câncer.
BR112021018611A 2019-03-20 2020-03-20 Anticorpos tendo especificidade para btn2 e usos dos mesmos BR112021018611A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305345 2019-03-20
EP19219691 2019-12-24
PCT/EP2020/057794 WO2020188086A1 (en) 2019-03-20 2020-03-20 Antibodies having specificity for btn2 and uses thereof

Publications (1)

Publication Number Publication Date
BR112021018611A2 true BR112021018611A2 (pt) 2021-11-23

Family

ID=69810881

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021018611A BR112021018611A2 (pt) 2019-03-20 2020-03-20 Anticorpos tendo especificidade para btn2 e usos dos mesmos

Country Status (12)

Country Link
US (1) US20220162305A1 (pt)
EP (1) EP3941940A1 (pt)
JP (1) JP2022525937A (pt)
KR (1) KR20220007041A (pt)
CN (1) CN113811545A (pt)
AU (1) AU2020243076A1 (pt)
BR (1) BR112021018611A2 (pt)
CA (1) CA3134122A1 (pt)
IL (1) IL286486A (pt)
MX (1) MX2021011334A (pt)
SG (1) SG11202109932WA (pt)
WO (1) WO2020188086A1 (pt)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2156725A1 (en) 1993-02-22 1994-09-01 Warren S. Pear Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6018032A (en) 1995-09-11 2000-01-25 Kyowa Hakko Kogyo Co., Ltd. Antibody against human interleukin-5-receptor α chain
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU7071598A (en) 1997-04-10 1998-10-30 Erasmus University Rotterdam Diagnosis method and reagents
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
WO2006116192A2 (en) * 2005-04-21 2006-11-02 Medarex, Inc. Irta-1 antibodies and their uses
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
GB0717101D0 (en) * 2007-09-03 2007-10-10 Cambridge Entpr Ltd Tumour marker
BR112012026766B1 (pt) 2010-04-20 2021-11-03 Genmab A/S Métodos in vitro para gerar um anticorpo igg heterodimérico, para a seleção de um anticorpo biespecífico, vetor de expressão, anticorpo igg heterodimérico, composição farmacêutica, e, uso de um anticorpo igg heterodimérico
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
US20160376364A1 (en) * 2013-11-29 2016-12-29 Csl Limited Method of treating cancer
JP6892431B2 (ja) * 2015-07-10 2021-06-23 ゲンマブ エー／エス 癌治療用のａｘｌ特異的抗体−薬物コンジュゲート
EP3419999B1 (en) * 2016-02-26 2021-08-04 (INSERM) Institut National de la Santé et de la Recherche Médicale Antibodies having specificity for btla and uses thereof
CA3074933A1 (en) 2017-09-21 2019-03-28 Imcheck Therapeutics Sas Antibodies having specificity for btn2 and uses thereof

Also Published As

Publication number Publication date
JP2022525937A (ja) 2022-05-20
MX2021011334A (es) 2021-12-10
AU2020243076A1 (en) 2021-10-14
US20220162305A1 (en) 2022-05-26
CA3134122A1 (en) 2020-09-24
CN113811545A (zh) 2021-12-17
KR20220007041A (ko) 2022-01-18
SG11202109932WA (en) 2021-10-28
EP3941940A1 (en) 2022-01-26
WO2020188086A1 (en) 2020-09-24
IL286486A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
BR112018067525A2 (pt) anticorpos tendo especificidade para o btla e seus usos
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
BR112018070919A2 (pt) anticorpos anti-tim-3 e composições
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
BR112019008494A2 (pt) anticorpos para pd-1 e usos dos mesmos
EA201991556A1 (ru) Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции
EA201991214A1 (ru) Антитела против pd-1 и их композиции
GT201200318A (es) Anticuerpos hacia gdf8 humano
EA201891607A1 (ru) Axl-специфичные конъюгаты антитело-лекарственное средство для лечения злокачественных новообразований
BR112017001588A2 (pt) conjugados de anticorpo/fármaco anti-cdh6
MX2020013468A (es) Anticuerpos il-11ra.
BR112016024363A2 (pt) conjugado de anticorpo-fármaco e seu uso para tratamento de câncer
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
BR112016024525A2 (pt) novos anticorpos anti-rnf43 e métodos de uso
BR112018011177A2 (pt) conjugados de citarabina para terapia de câncer
BR112022003956A2 (pt) Anticorpos anti-cd73
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
EA201892287A1 (ru) Фармацевтические комбинации для лечения рака
BR112016024619A2 (pt) conjugado de anticorpo ao igf-1r-fármaco e seu uso para o tratamento de câncer
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.